Niu H, Wei H, Zhou X, Liu Y, Yang L, Wang Q
Biochem Genet. 2025; .
PMID: 39903433
DOI: 10.1007/s10528-025-11043-0.
Chi S, Wei F, Li Y, Yu L, Ma C, Fang Y
Transl Oncol. 2024; 51:102212.
PMID: 39591896
PMC: 11629338.
DOI: 10.1016/j.tranon.2024.102212.
Devaiah B, Singh A, Mu J, Chen Q, Meerzaman D, Singer D
Mol Cell. 2024; 84(22):4282-4296.e7.
PMID: 39454579
PMC: 11585421.
DOI: 10.1016/j.molcel.2024.09.030.
Kren B, Henzler C, Ahmed K, Trembley J
Mol Med. 2024; 30(1):175.
PMID: 39394061
PMC: 11476306.
DOI: 10.1186/s10020-024-00937-1.
Zhang S, Roeder R
Nat Struct Mol Biol. 2024; 32(1):98-112.
PMID: 39251822
DOI: 10.1038/s41594-024-01384-6.
An updated patent review of BRD4 degraders.
Ma Z, Zhang C, Bolinger A, Zhou J
Expert Opin Ther Pat. 2024; 34(10):929-951.
PMID: 39219068
PMC: 11427152.
DOI: 10.1080/13543776.2024.2400166.
BRD4: an effective target for organ fibrosis.
Wei Q, Gan C, Sun M, Xie Y, Liu H, Xue T
Biomark Res. 2024; 12(1):92.
PMID: 39215370
PMC: 11365212.
DOI: 10.1186/s40364-024-00641-6.
Compromised cell competition exhausts neural stem cells pool.
Li C, Zhang M, Du Y, Liu S, Li D, Zhang S
Cell Prolif. 2024; 57(12):e13710.
PMID: 39010274
PMC: 11628731.
DOI: 10.1111/cpr.13710.
Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis.
Zhang Y, Fong K, Mao F, Wang R, Allison D, Napier D
Cell Rep. 2024; 43(7):114431.
PMID: 38968071
PMC: 11334074.
DOI: 10.1016/j.celrep.2024.114431.
Alternatively mechanistic insights into acetylation in p53-mediated transcriptional regulation of cancer cell-intrinsic PD-1.
Wen J, Yao H, Cao Z, Wang D
Fundam Res. 2024; 3(4):647-654.
PMID: 38933547
PMC: 11197762.
DOI: 10.1016/j.fmre.2022.03.012.
Novel BRD4-p53 Inhibitor SDU-071 Suppresses Proliferation and Migration of MDA-MB-231 Triple-Negative Breast Cancer Cells.
Wang S, Lei K, Lai H, Liu T, Du L, Wu S
ACS Pharmacol Transl Sci. 2024; 7(4):1178-1190.
PMID: 38633583
PMC: 11019737.
DOI: 10.1021/acsptsci.4c00057.
Targeting super-enhancer activity for colorectal cancer therapy.
Voutsadakis I
Am J Transl Res. 2024; 16(3):700-719.
PMID: 38586095
PMC: 10994804.
DOI: 10.62347/QKHB5897.
Exploring Transcriptional Regulation of Beta Cell SASP by Brd4-Associated Proteins and Cell Cycle Control Protein p21.
Manji J, Pipella J, Brawerman G, Thompson P
Epigenomes. 2024; 8(1).
PMID: 38534794
PMC: 10968907.
DOI: 10.3390/epigenomes8010010.
Inhibition of CK2 Diminishes Fibrotic Scar Formation and Improves Outcomes After Ischemic Stroke via Reducing BRD4 Phosphorylation.
Li X, Yang Q, Jiang P, Wen J, Chen Y, Huang J
Neurochem Res. 2024; 49(5):1254-1267.
PMID: 38381246
PMC: 10991067.
DOI: 10.1007/s11064-024-04112-0.
NSD3 in Cancer: Unraveling Methyltransferase-Dependent and Isoform-Specific Functions.
Nunez Y, Vera S, Baeza V, Gonzalez-Pecchi V
Int J Mol Sci. 2024; 25(2).
PMID: 38256018
PMC: 10815784.
DOI: 10.3390/ijms25020944.
The complex nature of lncRNA-mediated chromatin dynamics in multiple myeloma.
Nylund P, Garrido-Zabala B, Kalushkova A, Wiklund H
Front Oncol. 2023; 13:1303677.
PMID: 38148842
PMC: 10750364.
DOI: 10.3389/fonc.2023.1303677.
Breaking the Silence: Regulation of HIV Transcription and Latency on the Road to a Cure.
Duggan N, Dragic T, Chanda S, Pache L
Viruses. 2023; 15(12).
PMID: 38140676
PMC: 10747579.
DOI: 10.3390/v15122435.
IDR-targeting compounds suppress HPV genome replication via disruption of phospho-BRD4 association with DNA damage response factors.
Wu S, Lai H, Sanjib Banerjee N, Ma Z, Santana J, Wei S
Mol Cell. 2023; 84(2):202-220.e15.
PMID: 38103559
PMC: 10843765.
DOI: 10.1016/j.molcel.2023.11.022.
BRD4 as a potential target for human papillomaviruses associated cancer.
Rani A, Bonam S, Zhou J, Li J, Hu H, Liu X
J Med Virol. 2023; 95(12):e29294.
PMID: 38100650
PMC: 11315413.
DOI: 10.1002/jmv.29294.
Methylation of BRD4 by PRMT1 regulates BRD4 phosphorylation and promotes ovarian cancer invasion.
Liu Y, Liu H, Ye M, Jiang M, Chen X, Song G
Cell Death Dis. 2023; 14(9):624.
PMID: 37737256
PMC: 10517134.
DOI: 10.1038/s41419-023-06149-5.